Impact of perioperative dexmedetomidine treatment on 1-year mortality in patients undergoing orthotopic heart transplantation

Torregroza, C; Endreß, CL; M'Pembele, R; Roth, S; Stroda, A; Aubin, H; Lichtenberg, A; Buse, GL; Huhn, R; Boeken, U

doi:10.1016/j.bjao.2025.100389

Cardiothoracic & vascular anesthesia

Impact of perioperative dexmedetomidine treatment on 1-year mortality in patients undergoing orthotopic heart transplantation

BJA OpenPublished 14 Mar 2025Retrospective cohort study

Main findingResultHazard ratio 0.25 95% CI 0.07–0.93

Read the original article ↗PubMed

Cite

Authors' conclusion

Perioperative dexmedetomidine treatment appears to be safe regarding 1-yr mortality in patients undergoing orthotopic heart transplantation.

Study context

Population: Patients undergoing orthotopic heart transplantation at the University Hospital Duesseldorf, 2011–2021, excluding postoperative extracorporeal life support267 screened
Participants: 169 patients

Exposure: Perioperative dexmedetomidine vs no dexmedetomidine
Dexmedetomidinen = 85
No dexmedetomidinen = 84reference
Outcome: Mortality
Follow-up: 1 yr after surgery

Methodological detailssingle-centre

Single-centre

Main finding

As reported in the abstract

Hazard ratio

0.25

95% CI 0.07–0.93

P = 0.03

By group

Dexmedetomidine4.9%

No dexmedetomidine15.5%

Dexmedetomidine vs No dexmedetomidine

HR 0.25 (95% CI 0.07–0.93); P = 0.03

Observational data: associations, not effects.

Original publication

Impact of perioperative dexmedetomidine treatment on 1-year mortality in patients undergoing orthotopic heart transplantation. BJA Open. Published 14 March 2025. doi:10.1016/j.bjao.2025.100389

Read the original article ↗

Composed by AI from the published abstract and checked against it. How Briefs are made →